Search results for: Precision Medicine
Filter search results
OHE responds to the NHS Ten Year Plan
3 July 2025
…precision medicine to predict and prevent illness is also an especially bold and necessary step towards a prevention-focused NHS. The underlying question however is how this will all be funded. …
Amanda Cole
30 May 2014
…drug development innovations require new reimbursement models, especially for multi-indication therapies, precision medicine, and gene therapies. She is keen to advance a research agenda for how real-world evidence can improve…
OHE’s submission to a parliamentary inquiry on UK drug shortages
6 October 2025
…when alternative medicines have received regulatory approval. Additionally, because rare diseases generally are chronic and seriously debilitating, people with rare diseases are likely to acutely feel the impacts of medicine…
Payment Models for Multi-Indication Therapies
1 November 2021
For the growing number of multi-indication medicines, access may be delayed or even denied due to challenges in linking payment with a medicine’s value across those indications. We assembled a…
OHE at iHEA: HTA in Emerging Markets, Personalised Medicine, EQ-5D mapping
6 August 2013
…Pharmaceutical Pricing in Developing Countries? from Office of Health Economics Profs Towse and Garrison both participated in a session on personalised medicine, orphan disease drugs and the future of health…
Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase
3 October 2019
…were viewed to be especially valuable in the context of rising NHS spending on medicines and the challenges in agreeing a new medicine’s price, which can potentially delay patient access…
Forecasting the UK Medicines Bill to 2014
7 November 2011
…a range of projections from it. To put medicines spending in context, Jon noted that approximately 14% of NHS operating costs in Scotland for 2009/10 were for medicines, compared to…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…(so called “Orphan Medicines”), in recognition of some of the inherent challenges around: High prices. Drug manufacturers often charge high prices for orphan medicines, in part due to the small…
A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”
1 May 2018
This OHE Consulting Report reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018) in which the authors…